ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Other Events

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Other Events

Story continues below

Item 8.01. Other Events.

On April10, 2017, Adaptimmune Therapeutics plc (the Company)
issued a press release announcing the closing of its previously
announced registered direct offering of its American Depositary
Shares (ADSs). The Company sold 7,000,000 ADS at a price of $6.00
per ADS. A copy of the press release is attached hereto as
Exhibit99.1 to this Current Report on Form8-K and is incorporated
herein by reference.

The opinion of Mayer Brown International LLP relating to the
legality of the ADSs is filed as Exhibit5.1 to this Current
Report on Form8-K and such opinion is incorporated by reference
into the registration statement on FormS-3 (Registration
No.333-212713) that was declared effective by the Securities and
Exchange Commission on September12, 2016 and into the prospectus
filed with the SEC on April5, 2017.

The Company also released an updated corporate presentation. The
updated corporate presentation materials are attached hereto as
99.2 and are incorporated by reference herein.

Item 9.01 Financial Statements and
Exhibits.

(d) Exhibits. The following exhibits are furnished as part of
this Report on Form8-K:

ExhibitNo.

DescriptionofExhibit

5.1

Opinion of Mayer Brown International LLP

23.1

Consent of Mayer Brown International LLP (included in 5.1)

99.1

Press Release dated April10, 2017

99.2

Adaptimmune Therapeutics plc corporate presentation dated
April2017


About ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP)

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Recent Trading Information

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) closed its last trading session up +0.06 at 5.76 with 232,341 shares trading hands.

An ad to help with our costs